Can a new pill keep stomach acid damage at bay?
NCT ID NCT07746518
First seen Aug 05, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This trial is testing an experimental drug called DWP14012 to see if it can prevent erosive esophagitis—a condition where stomach acid damages the esophagus—from coming back after it has healed. About 420 adults aged 19 to 75 with healed erosive esophagitis will take either DWP14012 or an active comparison drug daily for up to 24 weeks. The main goal is to see how many people stay in remission, meaning their esophagus remains healed, during that time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DWP14012 (an experimental acid-reducing drug)
- What this could lead to
- If successful, DWP14012 could offer a new option for people with healed erosive esophagitis to prevent the condition from coming back, potentially improving long-term management.
- What could go wrong
- This is a phase III trial, but results are not yet known. The drug may not be more effective than existing treatments, and side effects are possible. Success in this trial does not guarantee regulatory approval.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALED EROSIVE ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.